NCT00310843已完成不适用
A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 889
- 试验地点
- 102
- 主要终点
- Endpoints: relationship between nevirapine-related AEs and genetic polymorphisms loci: Drug metabolizing enzymes (e.g., cytochrome P450 isoforms) Drug transporters (e.g., MDR1 and OATP-C) Human Major Histocompatibility Complex region genes
研究概览
简要总结
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion for Case
- •Male or female patients >=18 years of age with HIV-1 infection who experienced one or more of the following adverse reactions within the first 8 weeks of starting nevirapine therapy:
- •Grade 3 or 4 LFT elevation (ALT or AST > 5X ULN) and any symptom consistent with clinical hepatitis (see Appendix 10.1)
- •Acute liver failure secondary to nevirapine therapy*
- •Functional group III or IV rash
- •*Acute liver failure is defined as serious liver injury usually requiring hospitalization that may lead to death or liver transplantation.
- •Inclusion for Control
- •Male or female patients >=18 years of age with HIV-1 infection who have been exposed to nevirapine therapy for at least 18 weeks and who do not meet any of the case inclusion criteria
排除标准
- •Exclusion for Cases
- •Patients with any hepatotoxicity or rash event which in the investigators judgement is not related to nevirapine use (ex. hepatotoxicity due to alcohol or other medicinal use or rash due to other medicinal use).
- •Patients who began abacavir or TMP-SMX (trimethoprim/sulfamethoxazole) therapy 2 weeks or less prior to or up to 8 weeks after initiating nevirapine therapy.
- •Patients with AST or ALT elevations > 5 times the ULN (>= Grade 3) just prior to the initiation of nevirapine therapy.
- •Exclusion for Controls
- •Patients who discontinued nevirapine before completing 18 weeks of dosing with 200 mg/day for 2 weeks followed by 400 mg/day thereafter.
- •Patients who developed functional group I, IIa or IIb rash within 18 weeks of starting nevirapine therapy, or any dermatologic condition that could plausibly be attributed to nevirapine.
- •Patients with ALT or AST elevations >2.5 X ULN (>Grade 1) within 18 weeks of starting nevirapine therapy.
- •Any hepatobiliary adverse event that could possibly be attributed to nevirapine.
- •Patients who develop any systemic reaction attributable to nevirapine use during the first 18 weeks of nevirapine treatment such as flu-like symptoms, arthralgia, myalgia, or conjunctivitis.
- •Exclusion for Cases and Controls
- •Patients who have participated in the 2NN-Long-term Follow-up study (1100.1454)
- •Patients with CD4 count 150 cells/mm3 prior to the initiation of nevirapine therapy (last available result measured 6 months prior to the initiation of nevirapine therapy).
- •Evidence of acute co-infection with viral hepatitis.
- •Patients taking prednisone, prednisolone, or immuno-modulatory medication within the first 8 weeks of nevirapine therapy.
- •Patients who are unwilling to provide blood samples for DNA testing.
- •Patients who did not sign informed consent and or authorization to release protected health information per local requirements.
- •Patients without available liv
研究组 & 干预措施
All study population
干预措施: Nevirapine (Drug)
结局指标
主要结局
Endpoints: relationship between nevirapine-related AEs and genetic polymorphisms loci: Drug metabolizing enzymes (e.g., cytochrome P450 isoforms) Drug transporters (e.g., MDR1 and OATP-C) Human Major Histocompatibility Complex region genes
次要结局
- Descriptive demographics comparing cases with matched controls in an attempt to link genetic polymorphisms associated with symptomatic hepatotoxicity or severe cutaneous toxicity (cases) to gender, race or other patient characteristics.
研究者
研究点 (102)
Loading locations...
相似试验
招募中
不适用
Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological MarkersDrug-Related Side Effects and Adverse ReactionsNCT03938597The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)10
已完成
不适用
Pharmacogenomic Study (Adjuvant Chemotherapy)Gastric CancerNCT01470404Samsung Medical Center792
已完成
不适用
A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).Non Small Cell Lung CancerNCT06196424Fondazione Policlinico Universitario Campus Bio-Medico336
Unknown
不适用
Adverse Events and Genomics in SchizophreniaAdverse Effect of Other Antipsychotics and NeurolepticsNCT01966588University of British Columbia100
已完成
不适用
Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT02893605Centre Hospitalier Universitaire de Nīmes800